Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Statin + aspirin refers to a fixed-dose combination of a statin (such as atorvastatin or rosuvastatin) and the antiplatelet agent aspirin. Statins are HMG-CoA reductase inhibitors that lower cholesterol by inhibiting the enzyme responsible for cholesterol synthesis in the liver. Aspirin is an antiplatelet agent that irreversibly inhibits cyclooxygenase-1 (COX-1), reducing thromboxane A2 production and thereby inhibiting platelet aggregation. The combination is primarily used for secondary prevention of cardiovascular events such as heart attack and stroke in patients at high risk due to established cardiovascular disease or multiple risk factors. This dual therapy targets both lipid lowering (statins) and reduction of thrombotic events (aspirin), providing additive benefits in reducing major adverse cardiovascular outcomes[2][4][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on statin + aspirin.